BRCA1_2数据解读中国专家共识(2021版)

2021-06-20 中华医学会病理学分会 中华病理学杂志.2021.50(6): 565-571.

乳腺癌易感基因(breast cancer susceptibility gene,BRCA)包括BRCA1和BRCA2,是重要的抑癌基因,其编码产物参与DNA损伤同源性重组修复。BRCA1/2基因检

中文标题:

BRCA1_2数据解读中国专家共识(2021版)

发布日期:

2021-06-20

简要介绍:

乳腺癌易感基因(breast cancer susceptibility gene,BRCA)包括BRCA1和BRCA2,是重要的抑癌基因,其编码产物参与DNA损伤同源性重组修复。BRCA1/2基因检测在卵巢癌、乳腺癌、胰腺癌、前列腺癌等相关肿瘤的遗传风险评估、治疗选择、预后判断等方面具有重要意义。变异解读是BRCA1/2基因检测中一个关键的环节。BRCA1/2基因变异解读需要依据各类信息(包括来自群体数据库、疾病数据库、文献和家系情况等)进行综合评判。为结合临床实践并补充相关领域更新,编写组在2017版《BRCA数据解读中国专家共识》基础上,增加了对肿瘤BRCA1/2基因变异解读的阐述,并对BRCA1/2基因检测报告等内容进行了一些细节上的更新,以进一步指导与规范我国BRCA1/2基因检测数据的解读和临床应用。

下载附件:

(因为版权问题,不支持下载)

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1084419, encodeId=5a5b10844192b, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd1e6424232, createdName=ms4000001698350784, createdTime=Sun Dec 26 15:54:33 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073783, encodeId=7aa210e37834b, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f65637290, createdName=ms4000000969798249, createdTime=Thu Nov 25 10:40:29 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998561, encodeId=74a7998561ed, content=如何获得原文啊?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1651299261, createdName=entl949, createdTime=Sun Jul 11 19:48:49 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978961, encodeId=72529e8961cc, content=求渠道, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499a5471373, createdName=ms7000000108845907, createdTime=Fri Jul 02 11:54:08 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
    2021-12-26 ms4000001698350784

    很实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1084419, encodeId=5a5b10844192b, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd1e6424232, createdName=ms4000001698350784, createdTime=Sun Dec 26 15:54:33 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073783, encodeId=7aa210e37834b, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f65637290, createdName=ms4000000969798249, createdTime=Thu Nov 25 10:40:29 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998561, encodeId=74a7998561ed, content=如何获得原文啊?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1651299261, createdName=entl949, createdTime=Sun Jul 11 19:48:49 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978961, encodeId=72529e8961cc, content=求渠道, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499a5471373, createdName=ms7000000108845907, createdTime=Fri Jul 02 11:54:08 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
    2021-11-25 ms4000000969798249

    好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1084419, encodeId=5a5b10844192b, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd1e6424232, createdName=ms4000001698350784, createdTime=Sun Dec 26 15:54:33 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073783, encodeId=7aa210e37834b, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f65637290, createdName=ms4000000969798249, createdTime=Thu Nov 25 10:40:29 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998561, encodeId=74a7998561ed, content=如何获得原文啊?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1651299261, createdName=entl949, createdTime=Sun Jul 11 19:48:49 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978961, encodeId=72529e8961cc, content=求渠道, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499a5471373, createdName=ms7000000108845907, createdTime=Fri Jul 02 11:54:08 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
    2021-07-11 entl949

    如何获得原文啊?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1084419, encodeId=5a5b10844192b, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd1e6424232, createdName=ms4000001698350784, createdTime=Sun Dec 26 15:54:33 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073783, encodeId=7aa210e37834b, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8f65637290, createdName=ms4000000969798249, createdTime=Thu Nov 25 10:40:29 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998561, encodeId=74a7998561ed, content=如何获得原文啊?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1651299261, createdName=entl949, createdTime=Sun Jul 11 19:48:49 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978961, encodeId=72529e8961cc, content=求渠道, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499a5471373, createdName=ms7000000108845907, createdTime=Fri Jul 02 11:54:08 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
    2021-07-02 ms7000000108845907

    求渠道

    0

拓展阅读

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组(统称) · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2010版)

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议:乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南:乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南:激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12